Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash from Financing Activities (2016 - 2025)

Surgery Partners' Cash from Financing Activities history spans 12 years, with the latest figure at $59.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 23.33% year-over-year to $59.2 million; the TTM value through Dec 2025 reached -$57.3 million, down 121.87%, while the annual FY2025 figure was -$57.3 million, 121.87% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $59.2 million at Surgery Partners, up from -$84.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $229.8 million in Q4 2021 and bottomed at -$84.1 million in Q3 2025.
  • The 5-year median for Cash from Financing Activities is -$30.8 million (2023), against an average of $20.4 million.
  • The largest annual shift saw Cash from Financing Activities surged 601.75% in 2021 before it tumbled 1052.05% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $229.8 million in 2021, then decreased by 15.97% to $193.1 million in 2022, then crashed by 123.1% to -$44.6 million in 2023, then surged by 207.62% to $48.0 million in 2024, then grew by 23.33% to $59.2 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Cash from Financing Activities are $59.2 million (Q4 2025), -$84.1 million (Q3 2025), and -$62.6 million (Q2 2025).